Browse

Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer

DC Field Value Language
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorCho, Jae Yong-
dc.contributor.authorKim, Yeul Hong-
dc.contributor.authorKim, Jin Won-
dc.contributor.authorDi Bartolomeo, Maria-
dc.contributor.authorAjani, Jaffer A.-
dc.contributor.authorYamaguchi, Kensei-
dc.contributor.authorBalogh, Agnes-
dc.contributor.authorSanchez, Teresa-
dc.contributor.authorMoehler, Markus-
dc.date.accessioned2021-01-31T11:08:10Z-
dc.date.available2021-01-31T11:08:10Z-
dc.date.issued2017-10-
dc.identifier.citationClinical Cancer Research, Vol.23 No.19, pp.5671-5678-
dc.identifier.issn1078-0432-
dc.identifier.other5646-
dc.identifier.urihttps://hdl.handle.net/10371/173047-
dc.description.abstractPurpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy versus best supportive care (BSC) among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy. Experimental Design: Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity. The primary endpoint was immune-related progression-free survival (irPFS); secondary endpoints included PFS by modified World Health Organization criteria and overall survival (OS). Results: Of 143 patients screened, 57 were randomized to each arm. irPFS with ipilimumab versus BSC was not improved 2.92 months, 95% confidence interval (CI), 1.61-5.16 vs. 4.90 months, 95% CI, 3.45-6.54, HR = 1.44; 80% CI, 1.09-1.91; P = 0.097], resulting in study cessation. At study closeout, which occurred 8 months after the interim analysis, the median OS durations were 12.7 months (95% CI, 10.5-18.9) and 12.1 months (95% CI, 9.3-not estimable), respectively. Grade 3/4 treatment-related adverse events occurred in 23% of ipilimumab-treated patients, in whom diarrhea (9%) and fatigue (5%) were most frequent, and in 9% of active BSC-treated patients. Conclusions: Although ipilimumab at 10 mg/kg was manageable, it did not improve irPFS versus BSC. However, comparable median OS of approximately 1 year and a favorable safety profile support the investigation of ipilimumab in combination with other therapies for advanced gastric cancer. (C) 2017 AACR.-
dc.titleEfficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1158/1078-0432.CCR-17-0025-
dc.citation.journaltitleClinical Cancer Research-
dc.identifier.scopusid2-s2.0-85032002887-
dc.citation.endpage5678-
dc.citation.number19-
dc.citation.startpage5671-
dc.citation.volume23-
dc.identifier.urlhttp://clincancerres.aacrjournals.org/content/23/19/5671-
dc.identifier.rimsid5646-
dc.identifier.sci000412160500003-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse